US approves cell therapy injection for wrinkles

Jun 22, 2011

US regulators have approved a new type of therapy that uses a person's own skin cells to create an injectable cosmetic plumper to smooth out laugh lines, Fibrocell Science said Wednesday.

The approved late Tuesday the Pennsylvania-based company's application for license to market laViv, which uses a person's own collagen cells, multiplies them, and creates an injectable substance.

"LaViv is the first and only personalized aesthetic cell therapy approved by the FDA for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults," a company statement said.

"In clinical trials, laViv was well tolerated with the majority of being injection-site reactions that were of mild to moderate intensity and resolved within one week."

The company has a patent on a process of extracting and multiplying a person's known as fibroblasts, which are responsible for making collagen, the protein that keeps skin firm and resilient.

Fibrocell said the came after two randomized, double blind trials of 421 patients who received either laViv or a placebo in three three treatments about five weeks apart.

Those trials showed laViv "effectively improved the appearance of nasolabial fold wrinkles," the company said.

In one study, 57 percent of patients on laViv saw an improvement compared to 30 percent who received the , according to a summary of the research published by the New York Times.

In the other, 45 percent of patients receiving laViv thought they looked better afterward, compared to 18 percent in the .

Doctors' opinions were more reserved -- 33 percent in the first trial and 19 percent in the second trial said they saw an improvement in their patients from laViv, the report said.

The most common side effects were redness, pain, swelling or bruising at the injection site, the company said.

Further studies are necessary to see how long the treatment lasts. The follow-up studies to date have only spanned six months.

Doctors take a sample of cells from behind a patient's ear and send those cells to a lab where scientists replicate hundreds of millions of and freeze them until they are needed for treatment, a process that takes about 90 days.

"The concept of using a patient's own collagen-making cells is a revolutionary way to help treat nasolabial fold wrinkles and help restore a fresh appearance," said Robert A. Weiss, a clinical professor at Johns Hopkins School of Medicine one of the investigators on the trials.

"Since this is a biological process that works over time, laViv is able to provide gradual and natural-looking results."

Explore further: US announces $840M to improve medical care

add to favorites email to friend print save as pdf

Related Stories

Light-activated therapy may change skin at molecular level

Oct 20, 2008

Photodynamic therapy—which involves a light-activated medication and exposure to a light source—appears to produce changes at the molecular level in aging skin, according to a report in the October issue of Archives of ...

FDA approves a new beta blocker

Dec 18, 2007

The U.S. Food and Drug Administration has approved Bystolic, a beta blocker, for the treatment of high blood pressure. Bystolic (nebivolol) is a new drug not previously approved for use in the United States.

Recommended for you

User comments : 0